A genome-wide scan of ashkenazi jewish crohn's disease suggests novel susceptibility loci by Kenny, EE et al.
A Genome-Wide Scan of Ashkenazi Jewish Crohn’s
Disease Suggests Novel Susceptibility Loci
Eimear E. Kenny1¤, Itsik Pe’er1, Amir Karban2, Laurie Ozelius3, Adele A. Mitchell3, Sok Meng Ng4, Monica
Erazo3, Harry Ostrer5, Clara Abraham4, Maria T. Abreu6, Gil Atzmon7, Nir Barzilai7, Steven R. Brant8,9,
Susan Bressman10,11, Edward R. Burns12, Yehuda Chowers2, Lorraine N. Clark13, Ariel Darvasi14, Dana
Doheny3, Richard H. Duerr15,16, Rami Eliakim17, Nir Giladi18, Peter K. Gregersen19, Hakon Hakonarson20,
Michelle R. Jones21, Karen Marder22,23, Dermot P. B. McGovern24,25, Jennifer Mulle26, Avi Orr-Urtreger27,
Deborah D. Proctor4, Ann Pulver28,29, Jerome I. Rotter25, Mark S. Silverberg30, Thomas Ullman31,
Stephen T. Warren26,32, Matti Waterman2, Wei Zhang4, Aviv Bergman33, Lloyd Mayer31, Seymour Katz34,
Robert J. Desnick3, Judy H. Cho4*, Inga Peter3*
1Department of Computer Sciences, Columbia University, New York, New York, United States of America, 2Department of Gastroenterology, Rambam Health Care Campus, B.
Rappaport Institute for Research in the Medical Sciences, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, 3Department of Genetics and Genomic
Sciences, Mount Sinai School of Medicine, New York, New York, United States of America, 4Department of Medicine, Section of Digestive Diseases, Yale University, New Haven,
Connecticut, United States of America, 5Department of Pathology, Albert Einstein College of Medicine, New York, New York, United States of America, 6Division of
Gastroenterology, University of Miami Miller School of Medicine, Miami, Florida, United States of America, 7Genetic Core for Longevity, Institute for Aging Research and the
Diabetes Research Center, Albert Einstein College of Medicine, Bronx, New York, United States of America, 8Meyerhoff Inflammatory Bowel Disease Center, Department of
Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 9Department of Epidemiology, Bloomberg School of Public Health, Johns
Hopkins University, Baltimore, Maryland, United States of America, 10Mirken Department of Neurology, Beth Israel Medical Center, New York, New York, United States of
America,                                  The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, United States of America, 12Department of Medicine, Albert
Einstein College of Medicine, Bronx, New York, United States of America, 13Department of Pathology and Cell Biology, Columbia University, New York, New York, United States
of America, 14 The Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel, 15Division of Gastroenterology, Hepatology, and Nutrition, Department of
Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, 16Department of Human Genetics, Graduate School of Public Health,
University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 17Department of Gastroenterology and Hepatology, Sheba Medical Center, Raman Gan, Israel,
18Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel, 19Robert S. Boas Center for Genomics and
Human Genetics, Feinstein Institute for Medical Research, North Shore LIJ Health System, Manhasset, New York, United States of America, 20Center for Applied Genomics, The
Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America, 21Division of Endocrinology, Diabetes,
and Metabolism, Graduate Program in Biomedical Sciences and Translational Medicine, Cedars-Sinai Medical Center, Los Angeles, California, United States of America,
22Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America, 23 Taub Institute for Research on
Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America,24Department of Translational
Medicine, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, 25Medical Genetics
Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, 26Department of Human Genetics, Emory University School of Medicine, Atlanta,
Georgia, United States of America, 27Genetic Institute, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel, 28 Epidemiology-
Genetics Program in Schizophrenia, Bipolar Disorders, and Related Disorders, Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University,
Baltimore, Maryland, United States of America, 29Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States
of America, 30 IBD Group, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 31Division of Gastroenterology, Department of Medicine, Mount Sinai School of
Medicine, New York, New York, United States of America, 32Departments of Biochemistry and Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of
America, 33Department of Systems and Computational Biology, Albert Einstein College ofMedicine, New York, New York, United States of America, 34Albert Einstein College of
Medicine, North Shore University Hospital-Long Island Jewish Hospital Systems, St. Francis Hospital, Great Neck, New York, United States of America
Abstract
Crohn’s disease (CD) is a complex disorder resulting from the interaction of intestinal microbiota with the host immune system
in genetically susceptible individuals. The largest meta-analysis of genome-wide association to date identified 71 CD–
susceptibility loci in individuals of European ancestry. An important epidemiological feature of CD is that it is 2–4 times more
prevalent among individuals of Ashkenazi Jewish (AJ) descent compared to non-Jewish Europeans (NJ). To explore genetic
variation associated with CD in AJs, we conducted a genome-wide association study (GWAS) by combining raw genotype data
across 10 AJ cohorts consisting of 907 cases and 2,345 controls in the discovery stage, followed up by a replication study in 971
cases and 2,124 controls. We confirmed genome-wide significant associations of 9 known CD loci in AJs and replicated 3
additional loci with strong signal (p,561026). Novel signals detected among AJs were mapped to chromosomes 5q21.1
(rs7705924, combined p= 261028; combined odds ratio OR=1.48), 2p15 (rs6545946, p = 761029; OR= 1.16), 8q21.11
(rs12677663, p = 261028; OR=1.15), 10q26.3 (rs10734105, p = 361028; OR= 1.27), and 11q12.1 (rs11229030, p = 861029;
OR= 1.15), implicating biologically plausible candidate genes, including RPL7, CPAMD8, PRG2, and PRG3. In all, the 16 replicated
and newly discovered loci, in addition to the three coding NOD2 variants, accounted for 11.2% of the total genetic variance for
CD risk in the AJ population. This study demonstrates the complementary value of genetic studies in the Ashkenazim.
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Introduction
Ashkenazi Jews (AJs) comprise a single genetic community of
individuals of Eastern and Central European descent. Several lines of
evidence suggest genetic differences between the Jewish and non-
Jewish peoples of Europe (NJ). It has been demonstrated that the
genomes of individuals with one to four grandparents of Jewish
descent carry an unambiguous signature of their heritage allowing a
perfect inference of their Jewish ancestry [1].When studied separately,
Jewish populations represent a series of geographical clusters with each
group demonstratingMiddle Eastern ancestry and variable admixture
with European populations [2,3]. Moreover, Price et al. [4] have
shown that AJ ancestry is one of the major determinants of population
structure amongst disease groups of European Americans and can be
easily discerned by a small panel of genetic markers.
Genetic differences between Jewish and non-Jewish populations
have been detected in the context of multiple monogenic conditions
that are more prevalent in AJ populations. More than 25 recessive
disease founder alleles have been found to afflict Ashkenazi
populations at much elevated frequencies [5,6] compared to NJ
populations, resulting in a higher incidence of rare disorders
including Tay Sachs disease, Canavan, Niemann-Pick, Gaucher,
and others. Considerably higher frequencies of particular mutations
strongly associated with common diseases, such as breast cancer
(BRCA1 185delAG) [7] and Parkinson’s disease (LRRK2 G2019S)
[8] have also been detected in AJ compared to NJ. Moreover, a
three-phase genome-wide association study (GWAS) conducted in
an AJ population has identified a novel region on 6q22.33
associated with familial breast cancer risk [9].
Crohn’s disease (CD) is an inflammatory bowel disease resulting
from dysregulated mucosal immune responses to enteric microbi-
ota which arise in genetically susceptible individuals (reviewed in
[10]). CD is 2–4 times more prevalent among AJs compared to NJ
populations [11,12]. Association scans in predominantly NJ CD
studies have identified 71 susceptibility loci associated with the
disease risk including coding polymorphisms at NOD2, IL23R,
ATG16L1 and an intergenic region on chromosome 5p13
[13,14,15,16,17,18]. In our recent work, we showed that genetic
risks associated with CD in the AJ population for the 22 most
frequently replicated variants were similar to those reported in NJ
populations [19] and, therefore, are unlikely to explain the excess
disease prevalence in individuals of AJ descent. Although
underlying mechanisms responsible for ethnicity-specific differ-
ences may include epigenetic and environmental factors, it has
been hypothesized that substantially increased risk of CD in AJ
versus NJ can be explained through the involvement of yet
unknown genetic variants predominantly in this population.
Therefore, the goal of the present study was to conduct a
comprehensive GWAS to identify AJ-specific loci that predispose
to CD, by testing for association in participants of self-identified
and genetically verified AJ ancestry across multiple collections of
cases and controls.
Results
Confirming Ashkenazi ancestry of study participants
The population under examination in this study is a genetically
distinct group in terms of ancestry, thus it was especially important
to verify the genetic AJ ancestry of the study participants in the
discovery stage. We performed PCA to determine the main axis of
variation explaining the study cohort data. Results of the principal
component analysis (PCA), plotting the samples with the three
continental HapMap reference panels (European; CEU, African;
YRI and Asian; CHB and JPT) and seven panels from the Jewish
HapMap consortium consisting of one Ashkenazi Jewish, one
European Jewish, three Middle Eastern and two Sephardic Jewish
panels, are shown on Figure 1A. As expected, the first principal
component (PC 1) distinguishes Africans from non-Africans and PC
2 distinguishes East Asians from Africans and individuals of
European and Jewish ancestry (Figure 1A). Close examination of
within-continent variation was performed by repeating this analysis
excluding the CHB, JPT and YRI samples. Here we show that PC 1
distinguished European from Jewish ancestry (Figure 1B) and PC 2
shows a Middle Eastern to European cline of Jewish populations,
with the majority of AJ individuals (,80%) clustering distinctly from
other European Jewish populations. Most of the remaining AJ
samples (n=,500) are intermediate on a PC 1 cline between the AJ
cluster and the European (CEU) cluster (Figure 1B). Upon
examining the distribution of PC1 values in these samples, three
distinct modes were defined; Group 1 (PC1,20.005), Group 2
(PC1 20.039- 20.046) and Group 3 (PC1 20.036- 20.019)
(Figure 1C). We postulated, based on previous PCA analysis of AJ
individuals that groups 2 and 3 might represent individuals with
75% (one non-AJ grandparent) and 50% (one non-AJ parent or two
non-AJ grandparents) AJ ancestry, respectively (Table S1). To avoid
exclusion of individuals with partial AJ ancestry, we performed
association mapping within each group independently to control for
admixture effects, and combined the p-values from each group
under a meta-analysis design to construct a single test statistic.
Genome-wide association mapping of CD in AJ
population
Details of the initial discovery GWAS panels and an
independent AJ replication panel as well as the genotyping
platforms used are given in Table 1. The final filtered dataset used
for association mapping comprised 1,060,934 genotyped and
imputed markers across 3,016 individuals (Figure S1). The dataset
was divided into three groups according to AJ ancestry (Figure 1C).
Crohn’s Disease GWAS in Ashkenazi Jews
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Figure 2A shows the QQ-plots for 100%, 75% and 50% AJ
ancestry groups (groups 1, 2 and 3, respectively). In the case of
group 3, the p-values were overinflated (l=1.14) and were
corrected by genomic control to approximate normality uniform
distribution [20]. Figure 2B shows the combined score from all
three groups. Two known CD loci exceed the genome-wide
significance threshold: NOD2 (16q12; rs2076756; p,2.32610220)
and IL23R (1p31; rs11209026; p,9.4261029) [14,15,16,21]. In
addition, 11 other previously reported CD signals at p,1024 were
PUS10/REL (2p16.1; rs13003464; p,1.9861027), ATG16L1
(2q37; rs2241880; p,2.8861026), intergenic region .300 kb
upstream of PTGER4 (5p13.1; rs9292777; 6.9261025), IL3 (5q31;
rs3091338; p,4.8661025), HLA region (6p22.1; rs9258260), an
intergenic region on 8q24.13 (p,9.2561025), JAK2
(9p24.1;rs2230724; p,8.1161025), ZNF365 (10q21; rs1076165;
p,1.8661025), NKX2-3 (10q24.2; rs11190141; 9.861025),
PSMB10 (16q22.1; rs11574514; p,8.0561025) and CCL7/CCL2
(17q12; rs3091316; 1.9361025) [13,17]. The full set of SNPs
showing association signal at a level of p,1024 includes 616 SNPs
across 137 distinct regions. Finally, since strong signals are prone
to skew p-value distribution and can cause over-dispersion,
especially at the tail, we assessed the p-value distribution with
and without NOD2 SNPs. The signal at these loci persists even
after controlling for the strong signal at NOD2 (Figure 2B inset).
Replication studies in independent AJ samples identify
five novel regions associated to CD
We followed a region-centric strategy for replication. If a single
marker exceeded p,161024 in a ‘‘signal region’’ (defined by the
furthest up- and down-stream SNP in linkage disequilibrium (LD)
with the marker, r2.0.2), it was included in the replication dataset.
In the cases where a region contained multiple markers with
p,161024, 1–7 tag SNPs were selected from the region. The final
set of replication markers comprised 175 SNPs across 137 regions,
139 of which were successfully genotyped in the replication dataset
(see Table S2). Applying a standard genome-wide significance
threshold of 561028 for the combined discovery and replication
Figure 1. PCA analysis of the study participants. (A) PCA showing
the first (X-axis) and second (Y-axis) eigenvectors plotting all 3,252
study participants (907 CD cases and 2,345 controls) across ,22 K
unlinked SNPs indicated by light blue open circles. Also included and
color-coded in the graph are the four HapMap (www.hapmap.org)
reference samples as solid triangles; CEPH-Utah (CEU; green), Yoruban-
Nigeria (YRI; red), Han Chinese (CHB; orange) and Japanese (JPT; dark
grey); and seven Jewish samples from the Jewish Hapmap project [2] as
solid circles, consisting of Ashkenazi Jews (AJ; blue), one European
(Italian; purple), three Middle Eastern (Syrian; fuchsia, Iraqi; teal and
Iranian; turquoise) and two Sephardic Jewish cohorts (Turkey; brown
and Greek; orange). (B) The same analysis excluding the YRI and
CHB+JPT reference panels. (C) A histogram of PC1 values for study
participants (light blue) near the AJ cluster and intermediate between
the AJ and CEU clusters. The histogram of PC1 values for the included
samples show three distinct modes (Groups 1–3), with AJ reference
(blue) and CEU (green) indicated.
doi:10.1371/journal.pgen.1002559.g001
Author Summary
Crohn’s disease causes inflammation of the digestive tract
resulting from the interaction of normal gut bacteria with
the host immune system in genetically predisposed
individuals. People of Jewish heritage have an increased
risk of developing Crohn’s disease compared to non-
Jewish Europeans. So far, 71 genetic variants that increase
the risk of Crohn’s disease have been identified in
individuals of European ancestry. Here, we take advantage
of recent technical and methodological advances to
explore Crohn’s diseases-related genetic variants specific
to the Ashkenazi Jewish population. We examined 6,347
individuals whose Jewish ancestry was confirmed by a
large number of genetic markers and detected several
variants associated with the increased risk of Crohn’
disease. We confirmed the involvement of 12 known
Crohn’s disease risk variants in Ashkenazi Jews and
identified novel genetic regions not previously found in
non-Jewish European populations. Further studies of these
regions may help discover biological pathways affecting
susceptibility to Crohn’s disease and lead to the develop-
ment of novel treatments. This study also demonstrates
the complementary value of genetic studies in isolated
populations, like the Ashkenazim.
Crohn’s Disease GWAS in Ashkenazi Jews
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Table 1. Study cohort description.
Data Source Ntotal NCD cases Nnon-CD cases Ncontrols Platform
Discovery GWAS Panel
NIDDK IBD genetics consortiuma 828 397 - 431 Illumina 300 k
Pediatrics IBD Consortiuma 136 136 - - Illumina 550 k
Mount Sinai School of Medicine I 173 113 - 60 Affymetrix 500 k
Mount Sinai School of Medicine II 532 261 271 - Affymetrix 6.0
John Hopkins University 535 - 535 - Affymetrix 6.0
Albert Einstein College of Medicine 651 - - 651 Affymetrix 6.0
Hebrew University of Jerusalem 397 - 200 197 Illumina 300 k
Total 3,252 907 1,006 1,339
Replication Panel
Cedars-Sinai Medical Centerb 348 348 - - Illumina 610 k
NIDDK IBD genetics consortium 59 59 - - Illumina 1 M
Columbia University 444 - 267 177 Illumina 660 k
Tel Aviv Sourasky Medical Center 426 - 298 128 Affymetrix 6.0
Mount Sinai School of Medicine 1,254 203 - 1051 Sequenom/iPLEX
Connecticut-Long Island 142 142 - - Sequenom/iPLEX
Rambam Medical Center 445 239 - 203 Sequenome/iPLEX
Total 3,118 971 565 1,559
For each screen, the total number of individuals examined is shown (Ntotal), in addition to any Crohn’s disease cases (NCD_cases), non-Crohn’s disease cases, which are a
mix of individuals with Parkinson’s disease, Schizophrenia, Type-2 Diabetes and Dystonia, (Nnon-CD_cases), and non-diseased controls (Ncontrols).
bGenotypes available for only a subset of 31 replication markers.
doi:10.1371/journal.pgen.1002559.t001
Figure 2. Association mapping of Crohn’s disease in Ashkenazi Jews. (A) QQ-plots of the 100%, 75% and 50% AJ ancestry groups (Groups 1,
2 and 3, respectively). The inflation factors for the p-value distributions are given. For group 3, the p-values were genomic control-adjusted for over-
inflation. (B) A Manhattan plot and QQ-plot (inset – in black) of the combined association scores from all three groups. The genome-wide threshold is
shown in red and the replication threshold is shown in blue. The QQ-plot also shows association scores from all three groups but with 298 markers
around the region of the NOD2 signal on chromosome 16 removed before association mapping (in grey).
doi:10.1371/journal.pgen.1002559.g002
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signals, we observed 21 SNPs that surpassed this threshold in 14
distinct genetic regions (Table 2).
As positive controls, we report 9 of the 13 known loci listed in the
previous section exceeding our threshold of association in the AJ
population, with a further three surpassing our replication threshold
for known regions of association to CD, 561026 (Table 2 and Figure
S2). Furthermore, novel signals of association in the AJ sample were
observed for five regions not previously reported. Regional
association plots of all five novel regions are shown in Figure 3 and
their risk allele frequencies and odd ratios (ORs) are shown in Table 2.
Two of these regions (5q21.1; rs7705924; 1.7861028 and 10q26.3;
rs10734105; 3.3461028) contained just a single gene, SLCO6A1 and
TCERG1L, respectively, with moderate effects (OR.1.25). The other
three regions, rs6545946 (2p15; 7.0161029), rs12677663 (8q21.11;
1.9661028) and rs11229030 (11q12.1; 8.4561029), each contained
multiple candidate genes. Additionally, interrogation of publically
available eQTL databases revealed that rs6545946 correlated with
both CPAMD8 and AK3 expression [22]. Further investigation of a
gap next to the 11q12.1 peak of association detected a previously
reported 625 bp copy number variant (CNV) found in 1 Yoruban
(YRI) HapMap sample [23], which is,50 kb downstream of our top
SNP rs11229030. Also, in this region, 17 SNPs were filtered out due
to poor imputation quality.
Comparison of CD signals found in AJ to NJ European
ancestry-derived loci
We examined LD architecture at the five novel regions in AJ
and NJ CD cases from the Wellcome Trust GWAS [18] (Figure
S3). We found 85 pairs of variants .150 kb apart around the top
SNPs having r2.0.2 in AJs compared to one pair in NJs across all
5 loci. Sixty two out of the 85 linked pairs in AJs were detected at
5q21.1 versus 0 pairs in non-AJs.
To examine the established CD risks in AJ populations, we
compared the signals in 71 unique susceptibility loci for CD
identified in the largest meta-analysis of CD in NJ populations to
date [24] to those in our sample (Table S3). We note that 57
susceptibility loci passed quality control in our analysis, of which,
31 surpassed nominal significance and 30/31 showed effects in the
same direction in AJ as observed previously (p,6.9861024). We
selected a subset of these 30 loci for a direct comparison of genetic
Table 2. Regions identified in the Ashkenazi Jewish CD GWAS, replication, and combined association analyses.
SNP
Cytogenetic
location
Position
(MB)a
Candidate Genesb
(by genetic location ±250 kb)
Risk Allele
(Freq)c
OR
(95% CI)d
Discovery
p-valuee
Replicationp-
valuef
Combined
p-valueg
Association of novel gene regions:
rs6545946 2p15 62.57 TMEM17, EHBP1, ¤CPAMD8(5.7),
¤AK3(5.5)
C (0.770) 1.16(1.06–1.27) 3.0361026 2.3161023 7.0161029
rs7705924 5q21.1 101.98 SLCO6A1 G (0.066) 1.48(1.17–1.87) 3.7761025 4.7261024 1.7861028
rs12677663 8q21.11 74.17 C8orf84, TERF1, RPL7, RDH10, KCNB2 T (0.659) 1.15(1.04–1.28) 9.4661027 2.0861022 1.9661028
rs10734105 10q26.3 133.06 TCERG1L G (0.375) 1.27(1.10–1.43) 9.8061025 3.4161024 3.3461028
rs11229030 11q12.1 56.96 Multiple, including SLC43A3, PRG2,
PRG3
C (0.305) 1.15(1.10–1.39) 4.0161025 2.1161024 8.4561029
Association of previously known regions at genome-wide significance:
rs11209026 1p31.3 67.48 IL23R, IL12RB2, C1orf141, SERBP1,
SLC35D1
G (0.921) 2.20(2.10–2.35) 9.4261029 1.59610210 1.49610218
rs13003464 2p16.1 61.04 PUS10, PEX13, REL, KIAA1841,
C2orf74, PAPOLG, USP34
G (0.487) 1.05(1.00–1.40) 1.9861027 2.461022 4.7361029
rs2241880 2q37.1 233.84 ATG16L1, SAG, DGKD, INPP5D, USP40 G (0.601) 1.32(1.24–1.41) 2.8861026 5.0261027 1.44610212
rs9292777 5p13.1 40.31 PTGER4 T (0.597) 1.37(1.28–1.48) 6.9261025 9.1261027 2.13610211
rs3091338 5q31.1 131.43 IL3, ACSL6, P4HA2, PDLIM4, SLC22A4 T (0.328) 1.23(1.08–1.42) 4.8661025 9.2061024 4.4761028
rs9258260 6p22.1 29.83 HLA-F, MOG, HLA-G, GABBR1, HLA-H,
UBD, HLA-A
T (0.104) 1.45(1.21–1.68) 2.1961025 7.9261026 1.74610210
rs7076156 10q21.2 64.09 ZNF365, ERG2, ADO G (0.751) 1.19(1.10–1.30) 1.8661025 3.9161024 7.2961029
rs2076756 16q12.1 49.3 NOD2, CYLD, SNX20, NKD1 G (0.246) 1.66(1.48–1.88) 2.32610220 5.87610218 1.36610237
rs3091316 17q12 29.62 CCL7, CCL2, CCL11, CCL8, CCL13, CCL1 G (0.732) 1.14(1.03–1.27) 1.9361025 2.0261023 3.8961028
Replication of previously known regions:
rs1906493 8q24.13 127.16 Intergenic A (0.432) 1.19(1.09–1.28) 9.2561025 3.1861022 2.9461026
rs11190141 10q24.2 101.28 NKX2-3, SLC25A28, GOT1, ENTPD7,
CNNM1, COX15, CUTC
C (0.739) 1.34(1.25–1.43) 9.8061025 5.1961023 5.0861027
rs11574514 16q22.1 66.53 Multiple, including PSMB10 A (0.045) 1.44(1.35–1.52) 8.0561025 2.5661023 2.0661027
aPhysical position in megabases; Genome build NCBI36/hg18.
bGenes highlighted by genetic location of the top SNP 6250 kb, ordered by proximity to the top SNP. If the top SNP is intragenic, the gene is indicated in bold font.
Additionally, if there is evidence of eQTL effect of LOD$5 this is indicated with a ¤ symbol and the LOD is given in brackets.
cThe risk allele in the AJ cohort with its frequency in healthy controls given in parenthesis.
dThe odds ratio for the risk allele in the replication cohort, with 695% confidence intervals given in parenthesis.
e,f,gp-values for the initial discovery GWAS for Crohn’s disease in Ashkenazi Jews (Discovery p-value), replication cohort (Replication p-value) and a combined score of
both p-values (Combined p-value) are given. Association significance thresholds are 561028, 0.05, and 561028 for discovery, replication and combined p-values,
respectively. The significance thresholds of gene regions previously associated in other cohorts are 561026, 0.05 and 561026 for discovery, replication and combined p-
values, respectively.
doi:10.1371/journal.pgen.1002559.t002
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variance explained at susceptibility loci in NJ and AJ. Assuming
similar effect sizes in both populations, we had .80% power to
detect variants conferring OR$1.22 at the nominal significance of
0.05, assuming a minor allele frequency of .20% in healthy
controls. At these thresholds, we were powered to examine signals
at 12 of the known loci in the AJ sample. Of the 12 loci, 11 passed
QC in our discovery panel. Greater than the nominal signal
(p,0.05) was observed for 9 of the 11 loci (Table S3), which
agreed with our expectation by chance (based on the power for
detection, the number of signals that had been expected to attain
p,0.05 is 10.1560.86). Specifically, all 9 loci with.0.85 power to
be detected were observed and altogether they explained 4.3%
and 3.7% of genetic variance in AJs compared to NJs, respectively
(Table S4). In all, with the three coding NOD2 mutations, 11
confirmed SNPs (excluding the NOD2 tagSNP rs2076756), and 5
newly-discovered variants, we can account for 11.2% of genetic
contribution for CD in AJs (Table S4).
Discussion
CD has been a forerunner for common-disease genetics,
demonstrating dozens of markers associated with disease prevalence
in NJ populations. Here, we report the first GWAS for CD in a
sizeable increased-risk AJ population. As expected, a significant
number of markers previously associated with CD in predominantly
non-Jewish European cohorts were also associated with CD risk in
the AJ population. That is, of the 57 loci reported in Franke et al.
[24] and successfully assayed in our study, we observed nominal
signal in same direction for 30 variants. Importantly, five novel loci
were identified that attained genome-wide significance.
We observed genome-wide significant association with subse-
quent replication in a novel region on chromosome 2p15.
Evidence of sizable, trans-acting eQTL effects of rs6545946 were
detected, which influence CPAMD8 (chromosome 19p13) and AK3
(chromosome 9p24). CPAMD8 belongs to the complement
component-3/alpha-2-macroglobulin (A2M) family of proteins
involved in innate immunity and damage control. Complement
components recognize and eliminate pathogens by leading to
direct pathogen injury or by mediating phagocytosis and
intracellular killing. CPAMD8 is expressed in a number of human
tissues, including the small intestine. In response to immune
stimulants, CPAMD8 expression has been shown to be markedly
up-regulated in cell culture [25]. AK3, or adenylate kinase, encodes
a GTP:ATP phosphotransferase that is found in the mitochondrial
matrix [26]. Of interest, a GWAS examining hematologic
parameters identified associations to the AK3 region with platelet
count and volume [27].
The GWAS and replication samples also showed combined
genome-wide significant evidence for association at 8q21.11 that
spans a number of genes, including RPL7 and KCNB2. RPL7,
ribosomal protein L7, has been established as an autoantigen
representing a frequent target for autoantibodies from patients
with systemic autoimmune diseases, such as systemic lupus
erythematosus and rheumatoid arthritis [28]. The humoral
autoimmune response to RPL7 apparently is driven by antigen
and is T cell dependent [29]. KCNB2 is a potassium voltage-gated
channel expressed in a number of tissues, including gastrointestinal
smooth muscle cells [30,31]. Cardiac left ventricular systolic
dimensions [32] and the common migraine is associated to a
region that includes KCNB2 [33].
The chromosome 11q12.1 association signal mapped to a broad
region that spans multiple genes, including SLC43A3, PGR2 and
PRG3. Solute carrier family 43, member 3 (SLC43A3) is a putative
transporter identified in a survey of microarray expression
databases as having endothelial cell specific expression across
multiple organs whose mRNA expression is enriched in macro-
phages and vascular endothelial cells [34]. Also in the region,
PGR2 and PRG3, proteoglycan 2 and 3, are eosinophil granule
Figure 3. Regional plots of five novel associations to Crohn’s disease in Ashkenazi Jews. Regional plots of the SNP p-values obtained in
the discovery GWAS for a6250 kb window around each of the 5 novel SNPs. The X-axis shows the chromosome and physical distance (kb), the left Y-
axis shows the negative base ten logarithm of the p-value and the right y-axis shows recombination activity (cM/Mb) as a blue line. The chromosomal
band is given above each plot. The replication SNP is indicated as a large red diamond, and linkage disequilibrium of surrounding SNPs with the
replication SNP is indicated by a scale of intensity of red color filling as shown in the legend at the upper right hand corner of each plot. The
combined discovery and replication p-value for the replication SNP is shown in blue, and is annotated with the SNP identifier and combined p-values.
The position and location of any copy number variation in the mapping intervals are shown as a black rectangle. Positions, recombination rates and
gene annotations are according the NCBI’s build 36 (hg 18).
doi:10.1371/journal.pgen.1002559.g003
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major basic proteins known as natural killer cell activators [35].
PGR2 is believed to be involved in antiparasitic defense
mechanisms as a cytotoxin and helminthotoxin, and in immune
hypersensitivity reactions, including allergies and asthma [36,37].
High levels of the proform of this protein are also present in
placenta and pregnancy serum [38]. PGR3 possesses similar
cytotoxic and cytostimulatory activities to PRG2. In vitro, PRG3
has been shown to stimulate superoxide production and IL8
release from neutrophils, and histamine and leukotriene C4 release
from basophils [39]. Furthermore, a rare copy number variant has
been reported in 1 YRI HapMap sample 34 kb downstream of the
top SNP [23].
In addition, we observed genome-wide significant evidence for
association on chromosome 10q26.3 that was subsequently
replicated at rs10734105. This region is devoid of established
coding genes and detailed functions of a single nearby gene
encoding for transcription elongation regulator 1-like protein
(TCERG1L) have not yet been reported. The most significant
chromosome 5q21.1 association signal was flanked by SLCO6A1
(solute carrier organic anion transporter family gene).
Notably, none of these novel variants have been identified by
the largest CD meta-analysis of individuals of European descent
[24], which was sufficiently powered to detect effect sizes reported
by the present study. However, we observed substantial differences
in LD architecture around the top hits across the 5 novel signals.
These regions were enriched in variants .150 kb apart with
moderate and high LD (r2.0.2) compared to individuals of
European ancestry, which can, at least in part, explain the lack of
signal in non-AJs. Also, existence of rare variants in these regions
specific to this population cannot be ruled out.
Our data also suggest that refinement of causal alleles may
increase present estimates of heritability accounted for by presently
identified genetic loci. That is, the top GWAS SNP at the NOD2
locus in AJs appears to explain 1.5% of genetic variance, whereas
the three NOD2 coding mutations themselves account for 6.1%
(Table S4), which is slightly higher than in NJs (0.8% and 5%,
respectively [24]). Due to the historical population bottleneck and
subsequent isolation of AJs [40], it is possible that there are
population-specific rare variants in the newly discovered regions
contributing to CD susceptibility, reflecting allelic heterogeneity.
Therefore, resequencing analysis aimed at detecting the popula-
tion-specific rare variants in these regions may prove to be a more
successful approach to identify functional variants associated with
the disease. In all, with 19 variants, we can account for 11.2% of
genetic contribution for CD in AJs.
This study brings forth some lessons from using a specific,
isolated population in a large GWAS. First, as observed in other
contexts, self-declared ethnicity is an imperfect indicator of genetic
ancestry. Caution must be applied when considering samples
purported as part of a genetically distinct population. In this study,
we applied a mixed model of association, EMMAX [46], in each
group separately (100%, 75%, 50% AJ, Figure 1C), thereby
excluding 236 samples from analysis; of note is that among the
nine previously established loci which we were powered to
identify, we observed more significant evidence for association in
seven of these nine loci with this grouped approach, as opposed to
using a mixed model of association on the full cohort (data not
shown). An additional limitation of a study in an isolated
population is the availability of samples. In this case, we collected
samples across multiple diseases, and rely on CD being rare
enough for most of the individuals to be good controls for this
disease. While the reliance on multiple cohorts from various
studies exposes our study to concerns of platform-specific and center-
specific artifacts, these concerns are shared by many multi-center
GWAS published during the last few years. As such studies often
exchanged summary statistics for meta-analysis, our study had the
advantage of analyzing individual-level data at the same site and
controlling their quality uniformly.
The focus on the AJ population highlights the pros and cons of
conducting GWAS in a specific, isolated population versus more
outbred populations. On the one hand, we observe increased
detectability of some known common variants previously discov-
ered in NJ populations in this study. That is, we observed sizable
differences in the risk allele frequencies between AJ and NJ
controls for some SNPs, including IRGM rs7714584 (16.2% vs.
8.8%) and LRRK2 rs11564258 (5.6% versus 2.5%). While the
latter can be associated with the ascertainment bias related to the
inclusion of patients with Parkinson’s disease as non-disease
controls, the former trend was observed previously [19]. On the
other, some common variants that confer CD risk in NJ
populations, such as PTPN2 and TNFSF18, did not replicate in
the AJ panel despite sufficient power. While we assembled the
largest sample of CD patients of Ashkenazi descent to date,
potential explanations can include limited size, and therefore lack
of power. There have been no reported sub-phenotypic differences
in Crohn’s disease comparing Jewish and non-Jewish cohorts. Yet,
it is quite possible that different gene-environment interactions
could account for the distinct genetic loci identified. In addition,
our study design might have overlooked joint disease loci as many
of our controls were ascertained for several complex disorders.
Yet, our results follow observations in other isolated populations
[41,42] and delineate the distinct vs. shared repertoires of CD
causal variants in AJs vs. NJs, in addition to population differences
in patterns of LD between the causal variant and the detected
marker. Resolution of the source of these differences may become
available through high throughput sequencing in such samples.
Finally, looking ahead, the diversification of the population
studied in SNP-based association studies is likely to become even
more important with the current transition to sequencing.
Population genetics theory suggests that repertoires of rare,
recently-arising alleles would differ more between distinct and
isolated groups. This promises increased value for isolated
populations for sequencing studies that aim at dissecting the
genetics of complex diseases.
Materials and Methods
Ethics statement
The study was approved by the Institutional Review Boards at
all participating institutions, including the Mount Sinai School of
Medicine, Albert Einstein College of Medicine, New York
University, Hebrew University of Jerusalem, Yale University,
University of Pittsburgh, Johns Hopkins University, University of
Toronto, Columbia University, Tel Aviv Sourasky Medical
Center, Rambam Medical Center, Cedars-Sinai Medical Center,
and North Shore University Hospital-Long Island Jewish Medical
Center. All patients provided written informed consent (in English
or Hebrew) for the collection of samples and subsequent analysis.
Sample collection
Participants in this study were ascertained from 11 different
centers in the United States or Canada (New York, Philadelphia,
Los Angeles, Pittsburgh, New Haven, Baltimore and Toronto) and
Israel (Tel Aviv, Haifa and Jerusalem). In total, 6,370 individuals
who self-identified as AJ participated in the study. Blood samples
were taken with informed consent for DNA extraction. Standard
criteria that were used for the diagnosis of Crohn’s disease (CD) at
each center included the characteristic symptoms of chronic
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duration and objective validation, including endoscopic, radiologic
and/or pathologic confirmation [43].
The initial discovery GWAS analysis combined raw genotype
data obtained from genome-wide screening arrays across five
studies. The combined discovery AJ GWAS sample consisted of
907 CD cases and 2,345 ‘‘controls’’, where the control population
was made up of individuals ascertained as non-Crohn’s disease
(non-CD) cases (AJ individuals with Parkinson’s disease, Schizo-
phrenia, Type-2 Diabetes and Dystonia) or AJ individuals
ascertained as non-diseased controls (1,006 and 1,339, respective-
ly) (Table 1).
An independent AJ replication sample was used to validate
findings from the discovery GWAS. These included samples that
had been genotyped both on large-scale platforms and on custom
arrays. The final replication cohort consisted of 623 CD cases and
2,124 controls of AJ descent (565 and 1,559 non-CD cases and
non-disease controls, respectively). For a subset of 31 replication
markers, we included an extra 348 AJ cases genotyped using the
Illumina 610 k array. Details of all cases and controls genotyped
and the genotyping platforms used are given in Table 1.
Quality control (QC) measures for combining multiple
genome-scale datasets
We devised a strategy to combine the raw genotypes from nine
separate genome-scale datasets of variable size (59–1,067 individ-
uals) and case:control composition, that were genotyped across
several different platforms (Illumina 300 k, 500 k, 660 k and 1 M
and Affymetrix 500 k and 6.0) (see Text S1 for details). All of the
analyses were performed in PLINK [44]. The combined analysis
QC pipeline is shown in Figure S1.
AJ ancestry verification
PCA was conducted with smartpca software [45] using the
intersection of markers typed on all Illumina and Affymetrix
platforms in the combined dataset. We trained a coordinate
system across the ,22 K unlinked SNPs in the sample, including
the three continental Hapmap populations (Yoruban (YRI,
n = 167), combined Han Chinese and Japanese (CHB, n= 84
and JPT, n= 86) and European (CEU, n= 164)) and populations
from the Jewish Hapmap [2] of Middle Eastern Jews (Iraqi
(n = 40), Iranian (n = 32) and Syrian Jews (n = 25)), and European
origin Jews (Italian (n = 39), Ashkenazi (n = 35) and Sephardic
Jews from Greece (n = 44) and Turkey (n = 34)) (Figure 1A). The
analysis was repeated excluding the YRI, CHB and JPT samples.
Ancestry for all participants in the study was assessed by PCA
projection of their genotypes onto coordinates derived from
training on the reference panels. Individuals that clustered
distinctly with the Ashkenazi reference panel were deemed to
have 100% AJ ancestry (group 1) (Figure 1B). In addition, two
other groups of individuals that were intermediate between the
Ashkenazi and CEU reference panel clusters were included in the
subsequent analysis; individuals with 75% AJ:25% European
ancestry and 50% AJ:50% NJ, groups 2 and 3, respectively
(Figure 1C). Samples that fell outside group 1–3 modes as
determined by PCA analysis, were excluded from the study
(n = 236) (Table S1 and Text S1).
Constructing an AJ reference panel
Due to concerns over poor quality for imputed genotypes in AJ
samples using any of the standard HapMap reference panels, we
constructed a population-specific AJ reference panel comprised of
100 AJ individuals who had been typed on both the Affymetrix 6.0
and Illumina Omni1 platforms (see Figure S4 and Text S1).
Discovery GWAS
After cleaning and pruning for ancestry, the discovery GWAS
comprised a total of 2,994 participants, 737 CD cases and 2,257
controls. The discovery GWAS population was divided according
to AJ ancestry groups (Figure 1C). The final counts of CD cases/
controls in each group were: group 1 (100% AJ) 632/2,107, group
2 (75% AJ) 36/38 and group 3 (50% AJ) 69/212.
AJ populations are known to exhibit a high degree of cryptic
relatedness relative to outbred populations [5], therefore we
selected a mixed-model method for association, EMMAX, that
could account for any residual substructure of the AJ population
[46]. We tested for association to CD in each group separately. To
test for over-dispersion in the presence of strong effects, we
repeated the analysis excluding the top 7 NOD2 SNPs. Any over-
inflation of the p-value distributions was adjusted by genomic
control to approximate normality uniform p-value distribution
[20]. P-values were combined across the three groups using
METAL [47] (Text S1).
Replication
A total of 175 markers were selected for replication (Table S2).
The replication dataset consisted of participants with (a) confirmed
AJ ancestry genotyped on genome-scale Affymetrix and Illumina
platforms from QC-filtered cohorts which had not been included
in the discovery GWAS (n= 929) and (b) self-reported AJ ancestry
genotyped on custom Sequenom iPlex arrays (n = 1,841) (Table 1).
For a subset of replication markers (n = 31), we included additional
set (c) of CD cases with AJ ancestry identified by PCA and
genotyped on the Illumina 610 k platform (n = 348) (Table 1).
The direction of effect of markers surpassing nominal
significance in the replication dataset was compared between
both the discovery and replication datasets and markers that had
opposite effects were excluded. The one-tailed p-value of
replicating markers was then combined with the discovery p-value
using Fisher’s combined p-value method to produce the per-SNP
combined score.
Comparison to known European ancestry hits
Risk alleles and direction of effect were compared in both NJ
and AJ samples for concordance. Power calculations were
performed using the Genetic Power Calculator [48]. We also
compared LD architecture 250 kb upstream and downstream of
the novel hits between AJs and NJs using 1,748 CD cases of
European ancestry from the Wellcome Trust GWAS [18] by
assessing the number of SNP pairs located far apart with various
levels of linkage disequilibrium. Fraction of genetic variance
explained by the top risk alleles was assessed using the liability
threshold model of Risch [49] considering contributions to be
additive. The calculations were based on a prevalence of Crohn’s
disease in AJs of 1 per 100. For the coding NOD2 variants, we used
previously reported frequencies and effect sizes [19].
Supporting Information
Figure S1 Schema of combined analysis of discovery GWAS
dataset. Illumina (n = 3) and Affymetrix (n = 3) raw genotypes from
the different self-reported Ashkenazi (AJ) cohorts were quality
control filtered before being combined in three groups; Group
1=100% AJ, Group 2= 75% AJ: 25% Non-Jewish European (NJ)
and Group 3= 50% AJ:50%NJ. Missing variants within each
group were imputed from a specially constructed AJ reference
panel comprising 98 individuals sequenced on both Affymetrix
and Illumina platforms. Each group was then filtered for low
imputation score and minor allele frequency, and for batch effects
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between platforms and cohorts, to yield the final GWAS discovery
datasets.
(DOC)
Figure S2 Regional plots of known Crohn’s disease loci in
Ashkenazi Jews. Regional plots of the SNP p-values obtained in
the discovery GWAS for a 6250 kb window around each of the 5
novel SNPs. The X-axis shows the chromosome and physical
distance (kb), the left Y-axis shows the negative base ten logarithm
of the p-value and the right y-axis shows recombination activity
(cM/Mb) as a blue line. The chromosomal band is given above
each plot. The replication SNP is indicated as a large red
diamond, and linkage disequilibrium of surrounding SNPs with
the replication SNP is indicated by a scale of intensity of red color
filling as shown in the legend at the upper right hand corner of
each plot. The combined discovery and replication p-value for the
replication SNP is shown in blue, and is annotated with the SNP
identifier and combined p-values. Positions, recombination rates
and gene annotations are according the NCBI’s build 36 (hg 18).
(DOC)
Figure S3 Comparison of LD architecture between 100% AJ
CD cases and NJ CD cases (from WTCCC [18]) at 5 novel regions
of association from this study. Plots of linkage disequilibrium of in
a 6250 kb window around each of the 5 novel SNPs in 100% AJ
CD cases (n = 638) and European ancestry NJ cases from the
WTCCC [18] (n = 1,748).
(DOC)
Figure S4 Concordance between Illumina and Affymetrix
platforms Concordance was determined between individuals
(n = 100) and SNPs (n,195 K) that were genotyped on both the
Affymetrix 6.0 and Illumina 1 M platforms in the reference panel
(A) Shows the cumulative concordance between SNPs, where the
grey bar shows the cut off for inclusion in the reference panel and
(B) Shows the concordance per individual, where two individuals
with ,99.7% concordance were excluded.
(DOC)
Table S1 Ashkenazi Jewish ethnicity of study participants in
discovery GWAS cohorts. For each cohort (Data Source) in the
discovery GWAS, the total number of participants is shown.
Individuals with 100% Ashkenazi ancestry or either 75%:25% or
50%:50% Ashkenazi:European ancestry are shown (A J100, AJ75
and AJ50) as revealed by PCA analysis comparing these samples to
representative groups of European Ancestry (HapMap CEU) and
non-Ashkenazi Jewish Ancestry individuals (JHapMap [2]).
Individuals with ,50% Ashkenazi Jewish ancestry and/or non-
Ashkenazi Jewish ancestry are shown (Others) and were excluded
from the subsequent analysis.
(DOC)
Table S2 175 SNPs selected for replication. Replication
Region #: a region for replication containing $1 tag SNP
(each region is also banded alternatively with white or blue color
fill); dbSNP identifier: the unique rs identifier for each SNP
(dbSNP 130/hg18); Chromosome and Physical position: the
chromosomal and physical position of each SNP (hg18); Novel or
Known region?; if variants the region has been previously
associated with risk for CD in Franke et. al 2010 [24], noteworthy
gene(s) in the region are listed, otherwise the region is indicated
as ‘‘Novel’’; Discovery GWAS p-value; reported p-value in the
AJ panel for the discovery phase of this study; Minor allele;
minor allele in the AJ panel; Frequency of the minor allele;
frequency of the minor allele in all CD cases and controls;
frequency is also given for CD cases, non-CD disease controls
and controls stratified by cohort; Passed replication assay?;
whether the SNPs was successfully genotyped on the Sequenom
platform; Replication p-value; the p-value for association to CD
in the replication panel; Replicated p,0.05; yes if the replication
p-value,0.05; Combined p-value; the combined p-value for
association for SNPs that passed replication via Fishers
combined probability test of the discovery GWAS and
replication p-values; SCAN-P; p-value for the same SNP in the
discovery meta-analysis from the Franke et. al. study [24].
(DOC)
Table S3 Comparison of frequency, odds ratio and p-value in
the AJ panel for 71 SNPs associated to CD in mainly European
ancestry individuals in Franke et. al. 2010 [24]. SNP: the unique rs
identifier for each SNP (dbSNP 130/hg18); Chromosome and
Physical position: the chromosomal and physical position of each
SNP (hg18); Risk allele; the reported risk allele from the Franke et.
al. study in both populations; Freq, OR, P-value; comparing the
Non-Jewish individuals from Franke et al. [24] (NJ) to the
Ashkenazi panel reported here (AJ) given the frequency, odds
ratio and p-values for each of the 71 SNPs from the meta-analysis;
effect in same direction?; if the odds ratio for the reported risk
allele is in the same direction the ‘‘yes’’, otherwise, ‘‘no’’; AJ
nominal (p,0.05)?; if the discovery GWAS p-value (or replication
p-value where the associated SNP was the same in both studies) is
less than p,0.05 then ‘‘yes’’, otherwise, ‘‘no’’; Noteworthy genes;
interesting genes in the mapping interval for association. Assuming
similar effect sizes, we had .80% power to detect variants
conferring OR$1.22 at the nominal significance of 0.05, assuming
a minor allele frequency of .20% in healthy controls. At these
thresholds, we were powered to examine signals at 12 of the
known loci in the AJ sample (indicated as bolded rows in the
spreadsheet). Of the 12 loci, 11 were assayed in our discovery
panel. Greater than the nominal signal (p,0.05) was observed for
9 of the 11 loci which were then used for direct comparison of
signal for association to CD between NJ and AJ panels.
(DOC)
Table S4 Calculation of variance explained for 17 replicated
and associated SNPs from this study and 9 SNPs used for
comparison of NJ versus AJ signal at known associated loci. The
fraction of genetic variance explained was calculated for 17
replicated and associated SNPs from this study and 9 SNPs used
for comparison of NJ vs AJ, using the liability threshold model
given in Risch et al. [49], assuming an additive effect. We also
assumed a prevalence of CD in NJs to be 0.4% and 1% in AJs.
The calculation is coded as a macro in the excel spreadsheet
(columns B through AC).
(DOC)
Text S1 Supplemental material.
(DOC)
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